Eli Lilly and Company (LLY)
| Market Cap | 1.08T |
| Revenue (ttm) | 72.25B |
| Net Income (ttm) | 25.28B |
| Shares Out | 891.74M |
| EPS (ttm) | 28.15 |
| PE Ratio | 40.06 |
| Forward PE | 30.24 |
| Dividend | $6.92 (0.57%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 7,697,630 |
| Open | 1,128.80 |
| Previous Close | 1,127.69 |
| Day's Range | 1,128.00 - 1,215.76 |
| 52-Week Range | 623.78 - 1,215.76 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 1,222.62 (+1.2%) |
| Earnings Date | Aug 6, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Forecast
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,222.62, which is an increase of 1.20% from the latest price.
News
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today
The company has a diverse portfolio of medications.
GLP-1s linked to smell and taste impairment in diabetes patients
We also report on a potentially simple solution to nausea experienced by cancer patients receiving morphine for pain.
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly's pill, Foundayo, began shipping in April. In 2025, nearly half of all large employers co...
Eli Lilly’s Jaypirca recommended by CHMP for approval in EU
Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent Bruton tyrosine kin...
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Jo...
Eli Lilly announces more details of Medicare GLP-1 Bridge program
Eli Lilly (LLY) announced additional details regarding the Medicare GLP-1 Bridge program taking effect July 1. Under the program, Medicare Part D patients may be able to access Foundayo or…
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients b...
Eli Lilly price target raised to $1,232 from $1,119 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Eli Lilly (LLY) to $1,232 from $1,119 and keeps an Outperform rating on the shares.
Controversy Erupts Over Report Trump Has Early Access to Eli Lilly (LLY) Weight-Loss Drug
This is not the first controversy involving the U.S. president and drug maker.
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage...
Eli Lilly uses cash pile to fund untested drug development strategies, FT says
Eli Lilly (LLY) will be using its cash pile to fund untested drug development strategies in preparation for the expiration of patents on its weight-loss drugs, Patrick Temple-West of The…
Eli Lilly enters $1.9B research collaboration with Abbisko Therapeutics
Abbisko Therapeutics announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly (LLY). Under the agreement, the two companies will collaborate on the di...
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S. drugmaker told Reuters, as rival Novo Nordisk seeks to catch up i...
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Abbisko Cayman said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly.
Eli Lilly (LLY) to Launch Weight-Loss Pill in Europe Next Year
The company is waiting on regulatory approvals abroad.
How Eli Lilly Became a $1 Trillion Company
Mounjaro and Zepbound turned Eli Lilly into a trillion-dollar pharmaceutical giant. But every blockbuster drug eventually faces competition.
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate “stalking horse” asset sale agreements with Eli Lilly (...
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market as it has done in th...
Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout
The tech sector is experiencing a sharp global sell-off today, dragging down chipmakers like Intel, AMD, Micron, and even the artificial intelligence (AI) darling – Nvidia. What's driving this weaknes...
Eli Lilly (LLY) Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries
The pharma giant is trying to diversify its pipeline of new medicines.
Eli Lilly (LLY) Is Growing Fast at a Fair Price Even Without an AI Story
Eli Lilly ($LLY) reported strong Q1 2026 results and increased its full-year outlook, and all of this without an artificial intelligence (AI) story. Yet the stock has lagged the S&P…
Centessa announces High Court approval for acquisition by Eli Lilly
Centessa (CNTA) which entered into a definitive agreement relating to its proposed acquisition by Eli Lilly (LLY), through a wholly owned subsidiary, announced that the High Court of Justice of…
Eli Lilly price target raised to $1,135 from $1,050 at Berenberg
Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly (LLY) to $1,135 from $1,050 and keeps a Hold rating on the shares.
Lilly declares third-quarter 2026 dividend
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common s...